Weekly Stream
Weekly Stream
Advertisement
Alexandre V. Hirayama, MDAggressive B-Cell Lymphoma | July 24, 2025
NKTR-255 plus liso-cel shows promise in boosting CD8+ CAR T cells and improving remission in R/R LBCL.
Doris Hansen, MDMyeloma | July 24, 2025
New CAR T and bispecific therapies are reshaping myeloma care. Here's what the latest data reveals.
Melissa BadamoT-Cell Lymphoma | July 24, 2025
Josie Ford, of Mass General Hospital, shared real-world efficacy and safety data on duvelisib and romidepsin in PTCL.
Philippe Armand, MD, PhDHodgkin Lymphoma | July 24, 2025
Should interim PET scans still guide Hodgkin lymphoma treatment? Experts debate imaging, SUV changes, and biopsy use in HL.
Mohamed Kharfan-Dabaja, MD, MBAT-Cell Lymphoma | July 24, 2025
Experts discuss T-cell lymphoma care, new therapies, transplant timing, and the role of NGS in treatment decisions.
Ruben A. Mesa, MDMyeloproliferative Neoplasms | July 24, 2025
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Advertisement
Advertisement
Advertisement